Comparing outcomes of single-port insufflation endoscopic breast-conserving surgery and conventional open approach for breast cancer

Fang Xie1,2†, Zi‑Han Wang3†, Shan‑Shan Wu4, Tian‑Ran Gang1, Guo‑Xuan Gao1, Xiang Qu1* and Zhong‑Tao Zhang1*

Abstract
Background: In the surgical treatment of breast cancer, the goal of surgeons is to continually create and improve minimally invasive surgical techniques to increase patients' quality of life. Currently, routine breast-conserving surgery is often performed using two obvious incisions. Here, we compare the clinical efficacy and aesthetic outcomes of a novel technique using one incision, called 'single-port insufflation endoscopic breast-conserving surgery' (SIE-BCS), vs. conventional breast-conserving surgery (C-BCS) in patients with early-stage breast cancer.

Methods: A total of 180 patients with stage I or stage II breast cancer participated in this study, of whom 63 underwent SIE-BCS and 117 underwent C-BCS. Logistic regression analysis was conducted to assess the risk of local recurrence and metastasis. Aesthetic outcomes were evaluated using the BREAST-Q scale.

Results: The mean operation time was significantly longer for SIE-BCS (194.9 ± 71.5 min) than for C-BCS (140.3 ± 56.9 min), but the mean incision length was significantly shorter for SIE-BCS than for C-BCS (3.4 ± 1.2 cm vs. 8.6 ± 2.3 cm). While both surgeries yielded similar BREAST-Q ratings for satisfaction with breasts and sexual well-being, SIE-BCS was associated with significantly better ratings for physical well-being (chest area) and psychological well-being. Additionally, SIE-BCS was associated with decreased rates of adverse effects of radiation. The preliminary analysis showed that SIE-BCS did not increase the risk of local recurrence or metastasis.

Conclusion: The novel single-port insufflation endoscopic assisted BCS technique is feasible, safe, and improves patients’ postoperative comfort and psychological well-being, as compared to the conventional technique.

Keywords: Breast cancer, Breast-conserving surgery, Endoscopic, Single-port, BREAST-Q scale

Background
Breast cancer is the most common malignancy among women worldwide [1–3]. Since surgery remains the mainstay of treatment for breast cancer, minimally invasive procedures are continually being created and improved upon. Indeed, advanced techniques, such as sentinel lymph node biopsy and endoscopic procedures, have led to the increased adoption of minimally invasive breast-conserving therapies (over mastectomy).
by patients diagnosed with breast cancer. Importantly, breast-conserving surgery (BCS) provides faster recovery and better body image satisfaction, with survival rates similar to those obtained using mastectomy [4–7].

Conventional BCS (C-BCS) is frequently performed by creating two incisions, one to facilitate local extended lumpectomy and the other to facilitate sentinel lymph node biopsy or axillary lymph node dissection. These incisions are a drawback of the procedure, as they can cause patients to experience dissatisfaction with their visible cosmetic outcome and self-perceived body image. To overcome this unresolved and ongoing detriment to BCS, we designed an improved surgical technique called single-port insufflation endoscopic BCS (SIE-BCS), which combines the advantages of being minimally invasive and breast-conserving while avoiding the creation of obvious incision wounds and scarring on the breast. In our experience, SIE-BCS provides improved aesthetic outcomes and equal clinical efficacy as compared to C-BCS. The present retrospective cohort study involving 180 breast cancer patients treated at Beijing Friendship Hospital over a 43-month period aimed to compare the clinical outcomes of SIE-BCS and C-BCS.

Methods

Ethics statement

All surgical procedures and details of informed consent were approved by the ethics committee of Beijing Friendship Hospital, Capital Medical University, Beijing, China (2016-P2-070-02).

Patient selection

We searched our hospital’s medical database for adult patients (age ≥18 years) who had undergone surgical treatment for stage I or II invasive breast cancer between March 2017 and July 2019. Inclusion in this study was based upon the following detailed clinical and pathological criteria: tumor constrained to the mammary gland (as confirmed by magnetic resonance imaging [MRI]); lesion diameter ≤3 cm; distance between the lesion and the nipple-areola complex >3 cm; free axillary lymph nodes (i.e., not significantly fused with the axillary vein or brachial plexus nerves); adequate glandular volume; Eastern Cooperative Oncology Group grade 0–2; and normal liver, kidney, and bone marrow function. Patients were excluded if they met any of the following criteria: comorbid cardiovascular disease, myocardial infarction, or cerebrovascular disease; any condition precluding general anesthesia or surgical treatment; history of another tumor within the past 5 years; pregnancy or lactation; tumor invading the skin or subcutaneous tissue (as confirmed by MRI or physical examination); persistently positive pathological margins; and risk of failure of postoperative radiological therapy. In addition, patients with widespread disease were excluded since local excision of a single region or segment of the breast tissue would be unable to achieve negative margins with a satisfactory cosmetic result. Ultimately, the patient cohort included 63 breast cancer patients who underwent SIE-BCS and 117 patients who underwent C-BCS (Table 1). The patients were followed up until May 26, 2022.

Surgical procedures

All surgeries were performed by a single surgeon (Dr. Xiang Qu) with the patients in a supine position and the ipsilateral arm in abduction at 90°. In general, 0.2 mL methylene blue was first injected around the areola to identify the sentinel lymph node, According to preoperative MRI and breast ultrasound results, we palpated the tumor edge and then injected 5 mL methylene blue 1 cm away from the tumor margin to confirm the extent of tumor resection endoscopically (Fig. 1a). After 15 min, a 2.5-cm single-port incision was made along the wrinkles in the axilla for sentinel lymph node biopsy. Intraoperatively, frozen-section pathological examination was used to determine whether axillary lymph node dissection was necessary. If the patient required axillary lymph node dissection, we would extend the original incision to approximately 4 cm. This part of the surgery was performed under direct vision.

SIE‑BCS procedure

We used a reusable laparoscopy equipment kit (Olympus Optical Co., Tokyo, Japan) that included optical and endoscopic instruments. SIE-BCS was performed via the same short axillary incision that was used to perform the sentinel lymph node biopsy. First, we subcutaneously inserted a water injection needle (Jinzhong Co., Shanghai, China; Fig. 1b) through the axillary incision and advanced it up to the area to be resected; we then injected approximately 100 mL of a normal saline solution containing epinephrine (dilution, 1:500) between the skin and the mammary gland in order to reduce blood loss. Second, we inserted a tunneler (Jinzhong Co., Shanghai, China; Fig. 1c) into the subcutaneous layer to reveal the potential space between the skin and the mammary gland. Third, we created an adequate working space by insufflating carbon dioxide at a rate of 8 L/min (pressure, 8 mmHg) through the single-port insufflation kit (HTKD-Hang T Port, Beijing, China; Fig. 1e), which included 4 plastic trocars on its surface. After insertion of endoscopic tools from the single-port insufflation kit, we dissected the Cooper ligament with endoscopic tissue scissors until the overlying skin and the mammary gland were completely separated (Fig. 1i). Next, we used an electrocautery to vertically section the mammary gland.
Table 1 Clinical data of the 180 study patients

| Variable                          | SIE-BCS (N = 63) | C-BCS (N = 117) | p value |
|-----------------------------------|------------------|-----------------|---------|
| Age (years)                       |                  |                 | 0.961   |
| Mean                              | 52.8 ± 8.7       | 54.0 ± 10.4     |         |
| Range                             | 35.0–66.0        | 19.0–70.0       |         |
| Prenopausal, n (%)                | 24 (38.1%)       | 41 (35.0%)      | 0.770   |
| Preinvasive carcinoma, n (%)      | 7 (11.1%)        | 10 (8.5%)       | 0.381   |
| Mucinous carcinoma, n (%)         | 3 (4.8%)         | 3 (2.6%)        |         |
| Invasive ductal carcinoma, n (%)  | 54 (85.7%)       | 102 (87.2%)     |         |
| Degree of tumor differentiation, n (%) |                  |                 | 0.011   |
| PR, n (%)                         |                  |                 |         |
| Positive                          | 47 (74.6%)       | 71 (60.7%)      | 0.061   |
| Negative                          | 16 (25.4%)       | 46 (39.3%)      |         |
| ER, n (%)                         |                  |                 | 0.619   |
| Positive                          | 51 (80.9%)       | 91 (77.8%)      | 0.011   |
| Negative                          | 12 (19.1%)       | 26 (22.2%)      |         |
| HER2, n (%)                       |                  |                 | 0.011   |
| Positive                          | 5 (7.9%)         | 27 (23.1%)      |         |
| Negative                          | 58 (92.1%)       | 70 (76.9%)      |         |
| Tumor location, n (%)             |                  |                 | 0.285   |
| Lateral upper quadrant            | 42 (66.7%)       | 67 (57.3%)      |         |
| Lateral lower quadrant            | 2 (3.2%)         | 8 (6.8%)        |         |
| Medial upper quadrant             | 17 (26.9%)       | 31 (26.5%)      |         |
| Medial lower quadrant             | 2 (3.2%)         | 11 (9.4%)       |         |
| SLNB or ALND, n (%)               |                  |                 | 0.452   |
| SLNB only                         | 49 (77.8%)       | 85 (72.6%)      |         |
| SLNB and ALND                     | 14 (22.2%)       | 32 (27.4%)      |         |
| pT staging, n (%)                 |                  |                 | 0.672   |
| pT1                               | 45 (71.4%)       | 80 (73.8%)      |         |
| pT2                               | 18 (28.6%)       | 37 (26.2%)      |         |
| pN staging, n (%)                 |                  |                 | 0.517   |
| pN0                               | 46 (73.0%)       | 80 (68.4%)      |         |
| pN1                               | 17 (27.0%)       | 37 (31.6%)      |         |
| Degree of tumor differentiation, n (%) |                  |                 | 0.930   |
| G1                                | 6 (9.5%)         | 12 (10.3%)      |         |
| G2                                | 52 (82.5%)       | 94 (80.3%)      |         |
| G3                                | 5 (8.0%)         | 11 (9.4%)       |         |
| Tumor type, n (%)                 |                  |                 | 0.731   |
| Invasive ductal carcinoma         | 54 (85.7%)       | 102 (87.2%)     |         |
| Mucinous carcinoma                | 3 (4.8%)         | 3 (2.6%)        |         |
| Preinvasive carcinoma             | 6 (9.5%)         | 12 (10.2%)      |         |
| Tumor size (cm)                   | 1.90 ± 0.7       | 1.95 ± 0.8      | 0.440   |
| Range                             | 0.60–3.20        | 0.60–4.00       |         |

HER2 status was estimated using immunohistochemistry or in situ hybridization. Tumors were considered HER2 positive if the average immunohistochemistry showed (+++). The HER2 gene/chromosome 17 ratio was 2, and the average HER2 gene copy number was 6. SIE-BCS single-port insufflation endoscopic breast-conserving surgery; C-BCS conventional breast-conserving surgery; cTNM clinical tumor, node, and metastasis; ER estrogen receptor; PR progesterone receptor; HER2 human epidermal growth factor receptor type 2; SLNB sentinel lymph node biopsy; ALND axillary lymph node dissection; pT staging pathological tumor staging; pN staging pathological lymph node staging from its anterior surface to the pectoral fascia. The excision range was determined using the prior methylene blue injection (Fig. 1j). Finally, the retromammary space was separated with the electrocautery, and the pectoral muscle fascia was removed endoscopically. To prevent metastasis from the incision, we removed the tumor and surrounding tissues by using the tools provided in the single-port insufflation kit (Fig. 1k).

Intraoperative cryosection margin evaluation was performed to confirm the extent of tumor infiltration. If the result implied residual tumor cells, then additional resection and cryosection evaluation was performed until no residual tumor cells were found. If the cryosection pathology was positive more than twice, then a mastectomy was performed immediately.

Titanium clips were placed around the incision margin of the tumor to guide subsequent radiotherapy. A running suture of absorbable monofilament 3-0 barbed thread was used to close the residual cavity of the mammary gland. The surgical field was irrigated, and one drain was placed. The single axillary incision was sutured intradermally with a 4-0 absorbable suture. All 63 patients who underwent SIE-BCS also underwent postoperative radiotherapy, according to the National Comprehensive Cancer Network guidelines [8].

**C-BCS procedure**

First, we performed a sentinel lymph node biopsy through an axillary incision. In addition, a second incision was made on the skin over the tumor surface following the Langer lines. The tumor and the surrounding glandular tissues (within 1 cm of the lesion) were removed. The excisional area encompassed the mammary gland down to the pectoral fascia. After that, an intraoperative cryosection margin evaluation was performed. If the pathological findings indicated the presence of residual tumor cells, the resection was extended until the pathological results indicated that the incised margin was negative. Then, titanium clips were placed in the residual cavity to facilitate localizing the tumor area during postoperative radiotherapy. Finally, the surgical field was irrigated, and one drain was placed; the incision was sutured layer by layer.

**Cosmetic evaluation and patient satisfaction**

The aesthetic satisfaction of the patients was evaluated using the BREAST-Q scale [9, 10] at 6 months after the operation. BREAST-Q is a measurement tool that can reveal a patient’s postoperative quality of life and satisfaction with surgery. The BREAST-Q includes questions about the adverse effects of radiation, the patient’s psychosocial well-being, their physical well-being regarding the chest area, satisfaction with their breasts, and their...
sexual well-being. We compared the BREAST-Q scores between the two study groups.

**Statistical analysis**

Measurement data were expressed as mean ± standard deviation and range. Differences in patient age, tumor size, operation time, hospitalization duration, incision length, BREAST-Q scores, blood loss, total drainage volume, and drainage duration were determined using the independent-samples t test (normal distribution) or the Mann-Whitney U nonparametric test (non-normal distribution). Count data, such as lesion site, tumor stage, and hormone receptor status, were presented as absolute numbers and percentages. The Fisher exact test was used to determine between-group differences in the intraoperative cryosection results, and rates of local recurrence and metastasis. Differences in the baseline data between the two groups were compared using the chi-square test. The association of type of surgical technique with local recurrence and metastasis was analyzed using logistic regression after adjustments for operation type, tumor size, patient age, and human epidermal growth factor.

**Fig. 1**

a Injection of methylene blue to identify sentinel lymph nodes and tumor margin. The sentinel lymph nodes were identified by injecting methylene blue into the areola. To determine the resection range, we injected methylene blue 1 cm away from the tumor margin. The single-port incision was marked along the wrinkles in the axilla. b, c Needle and tunneler used for single-port insufflation endoscopic breast-conserving surgery. d, e The single-port insufflation kit. Carbon dioxide was introduced into the body cavity to create an adequate working space. The base plate is adjustable. f Injection of 0.5 mg of an adrenaline solution (0.9% sodium chloride; 250 mL) into the subcutaneous layer between the skin and the mammary gland to reduce blood loss. g Insertion of a tunneler into the subcutaneous layer to reveal the potential space between the skin and the mammary gland. h Insertion of endoscopic tools from the single-port insufflation kit. i After insufflation, the Cooper ligament was revealed between the skin and the mammary gland. The black arrow indicates the Cooper ligament under endoscopic view. j Vertical sectioning from the surface of the mammary gland to the pectoral fascia. The yellow star indicates the tumor location, and the yellow arrows show the dissection range, which was marked using methylene blue. k The single-port incision and the specimen.
receptor type 2 (HER2) status. SPSS version 22.0 software (IBM Corp., Armonk, NY, USA) was used for all statistical analyses. The threshold for a significant difference was set at \( p < 0.05 \).

**Results**

No insufflation-related complications, such as subcutaneous emphysema, were observed. In the SIE-BCS group, 49 patients underwent sentinel lymph node biopsy only, and 14 patients underwent axillary dissection in addition to sentinel lymph node biopsy. In the C-BCS group, 85 patients underwent sentinel lymph node biopsy, and 32 patients underwent sentinel lymph node biopsy plus axillary dissection (Table 1). The mean incision length was significantly shorter in the SIE-BCS group than in the C-BCS group (3.4 ± 1.2 cm vs. 8.6 ± 2.3 cm, \( p < 0.001 \)), while the operation time was significantly longer in the SIE-BCS group (194.9 ± 71.5 min) than in the C-BCS group (140.3 ± 56.9 min, \( p < 0.001 \)). The cost of hospitalization was significantly higher in the SIE-BCS group (44,067.1 CNY) than in the C-BCS group (41,693.9 CNY, \( p < 0.05 \); Table 2). None of the patients in the SIE-BCS group showed positive margins during cryosection analysis, while 2 patients in the C-BCS group showed positive margins and required an additional resection to achieve negative margins (0 vs. 1.7%, \( p > 0.05 \); Table 2).

Some patients in both groups experienced local recurrence and metastasis during the 43-month follow-up (Table 2). The rates of these secondary malignancies did not significantly differ between the two surgeries. Furthermore, when the surgery type, tumor size, patient age, and HER2 status were evaluated using logistic regression modeling for their potential as risk factors for the combined events of local recurrence and metastasis, none were found to be statistically associated with these events among our patient population (Table 3).

All our patients were assessed for personal subjective measures of psychological, physical, and sexual well-being at 6 months after their respective surgeries, via the BREAST-Q questionnaire. Compared to the patients who

**Table 2** Perioperative features of patients

| Variable                                      | SIE-BCS (N = 63) | C-BCS (N = 117) | \( p \) value |
|-----------------------------------------------|------------------|-----------------|--------------|
| Operation time (min)                          |                  |                 | < 0.001      |
| Mean                                          | 194.9 ± 71.5     | 140.3 ± 56.9    |              |
| Range                                         | 59.0–410.0       | 21.0–400.0      |              |
| Intraoperative blood loss (mL)                |                  |                 | 0.701        |
| Mean                                          | 24.3 ± 19.3      | 20.9 ± 15.2     |              |
| Range                                         | 5.0–0.0          | 2.0–50.0        |              |
| Margins during cryosection analysis, \( n \) (%) |                  |                 | 0.542        |
| Positive                                      | 0                | 2 (1.7%)        |              |
| Negative                                      | 63 (100%)        | 115 (98.3%)     |              |
| Tumor margin, \( n \) (%)                    |                  |                 |              |
| Positive                                      | 0                | 0               |              |
| Negative                                      | 63 (100%)        | 117 (100%)      |              |
| Incision length (cm)                          |                  |                 | < 0.001      |
| Median                                        | 3.0              | 8.0             |              |
| Q1–Q3                                         | 2.5–4.0          | 8.0–9.0         |              |
| Drainage duration (days)                      |                  |                 | 0.596        |
| Mean                                          | 4.3 ± 1.8        | 4.4 ± 1.7       |              |
| Range                                         | 1.0–10.0         | 2.0–8.0         |              |
| Total drainage volume (mL)                    |                  |                 | 0.041        |
| Mean                                          | 124.5 ± 102.0    | 87.5 ± 66.6     |              |
| Range                                         | 14.0–517.0       | 8.0–250.0       |              |
| Local recurrence, \( n \) (%)                |                  |                 | 0.916        |
| Positive                                      | 2 (3.2%)         | 2 (1.7%)        |              |
| Negative                                      | 2 (3.2%)         | 9 (7.7%)        |              |
| Metastasis, \( n \) (%)                      |                  |                 | 0.378        |
| Hospitalization cost (yuan)                  |                  |                 | 0.003        |
| Median                                        | 44,067.1         | 41,693.9        |              |
| Q1–Q3                                         | 41,552.9–47,015.4| 35,208.9–45,860.3|            |

*SIE-BCS* single-port insufflation endoscopic breast-conserving surgery, *C-BCS* conventional breast-conserving surgery
had undergone C-BCS, those who had undergone the novel SIE-BCS reported significantly better satisfaction scores for physical well-being regarding the chest area and psychological well-being. In addition, the adverse effects of radiation had less impact on the patients in the SIE-BCS group than on the patients in the C-BCS group. Patients in both groups reported statistically similar satisfaction rates for the physicality of their breasts and their sexual well-being (Table 4).

### Discussion

Although BCS is preferred for patients with early-stage breast cancer [11, 12], the conventional open technique often requires two surgical incisions, and the consequent scarring can negatively affect the postoperative aesthetics [13–15]. Indeed, patients’ postsurgical self-perception of health-related quality of life is being increasingly recognized as an important clinical outcome and considered in the therapeutic management of breast cancer. Integrating endoscopic technology in BCS, particularly for the treatment of early breast cancer, is a promising approach to respect these patients’ needs [16–19]. Herein, we describe our attempt at developing and implementing the novel SIE-BCS, which is a scarless technique, to improve disease management as well as patient satisfaction with the aesthetic outcome.

Previously, we had created an improved surgical technique to generate an adequate working space by using the skin-take-up kit [20]. For the newly created SIE-BCS technique, we found that the addition of carbon dioxide insufflation benefited the surgeon by greatly increasing the work space available to the surgical team, which facilitated their ability to perform the surgery through a single inconspicuous incision. In the report by Lai et al. [21], the method of creating the surgical space is slightly different from ours. Ozaki et al. [22] reported a similar procedure. In our experience, the work space created using carbon dioxide insufflation is better than that created using the hanging method.

In our clinical application of the novel SIE-BCS technique, all attempts were successfully completed, and there were no conversions to open surgery. Moreover, we did not find residual tumor cells after either breast-conserving technique (SIE-BCS or C-BCS), and clear resection margins were achieved in all patients. This overall outcome of our patients is better than that reported in the literature; in general, residual tumor cells at the resection margin are found in approximately 6.3% of cases [23]. We hypothesize that the low positive residual tumor cell rate in our study is attributable to the way our group determines the resection range. Before surgery, we palpate the tumor edge, add a 1-cm margin around the edge, and inject methylene blue along this margin, which is then used as the boundary for surgical resection. Our collective experience (postoperative gross pathology data not shown) indicates that the above method provides a resection size larger than the actual tumor, as compared to other detection methods, such as ultrasound examination.

From an aesthetic standpoint, the greatest benefit of the novel single-port endoscopic technique is related to its physical outcome. Requiring fewer incisions of shorter length than C-BCS, the SIE-BCS provides an aesthetic benefit, and this was further improved by the technique of following the natural wrinkles of the axilla to create the single-port incision, which is then hidden by the upper limb and the axillary fossa (Fig. 2a, b, and e). C-BCS typically requires two incisions on the surface of the breast (Fig. 2c, d, and f), and the readily visible scarring greatly reduces aesthetic satisfaction, with a greater potential for a negative impact on psychological well-being even after the cancer diagnosis is resolved. In other reports [21], double incisions around the axilla and areola were the most common incisions, accounting for 79% of surgeries. All our patients in the SIE-BCS group had a single axillary incision, so there was no surgical incision on the breast surface, which is a novel advantage of this technique. From a clinical standpoint, the SIE-BCS technique increased the operation time as compared to

### Table 3 Logistic regression analysis of multiple factors potentially associated with combined events of local recurrence and metastasis

| Variable          | Wald   | p value | OR    | 95% CI          |
|-------------------|--------|---------|-------|-----------------|
| SIE-BCS           | 0.036  | 0.849   | 0.886 | 0.255, 3.084    |
| Tumor size        | 1.270  | 0.260   | 0.969 | 0.917, 1.024    |
| Age               | 0.450  | 0.503   | 1.272 | 0.629, 2.573    |
| HER2 positivity   | 0.222  | 0.637   | 1.394 | 0.350, 5.548    |

OR: odds ratio, CI: confidence interval. SIE-BCS: single-port insufflation endoscopic breast-conserving surgery, HER2: human epidermal growth factor receptor type 2.

### Table 4 BREAST-Q scale scores of patients

|                      | SIE-BCS group (N = 63) | C-BCS group (N = 117) | p value |
|----------------------|------------------------|-----------------------|---------|
| Adverse effects of radiation | 65.1 ± 29.1            | 51.7 ± 22.4           | 0.03    |
| Physical well-being: chest     | 85.2 ± 19.8            | 64.7 ± 15.8           | < 0.001 |
| Psychological well-being   | 86.9 ± 16.4            | 75.2 ± 19.2           | 0.006   |
| Satisfaction with breasts     | 73.7 ± 18.3            | 68.8 ± 15.9           | 0.120   |
| Sexual well-being           | 61.6 ± 28.1            | 64.1 ± 24.0           | 0.600   |

BREAST-Q® version 2.0 © Memorial Sloan Kettering Cancer Center and The University of British Columbia, 2017. SIE-BCS: single-port insufflation endoscopic breast-conserving surgery, C-BCS: conventional breast-conserving surgery.
conventional surgery [24]; this phenomenon has been reported extensively, and examples of this can be found in gastrointestinal [25], hepatobiliary [26], and thyroid surgeries [27]. However, our clinical care teams do not begrudge the additional time and effort, in light of the benefits to the postoperative well-being of the patients (personal communications). Nonetheless, consideration of the increased operative cost due to the longer time and additional effort (surgeon skills, operative tools, etc.) is necessary, especially in countries where medical care costs fall on the patients or on insurance providers that operate for profit.

Another important finding in our comparison of the novel SIE-BCS technique and C-BCS is the different HER2 positivity rates between the two patient groups. Logistic regression analysis showed that choosing SIE-BCS did not increase the risk of local recurrence or metastasis. While HER2 positivity rate, tumor size, and age were not identified as independent risk factors for local recurrence and metastasis in our study cohort, other studies have identified these as risk factors for recurrence in patients undergoing endoscopic BCS [28, 29]. This inconsistency may be due to our smaller sample size and shorter follow-up period relative to those of the other studies. We have designed a prospective study to overcome these limitations. We hope that the completion of this prospective study will provide stronger and more extensive evidence for how the novel SIE-BCS technique can best be implemented for a wider range of patients to provide maximal benefit to their postsurgical health-related quality of life.

The BREAST-Q scores reported by our patients at 6 months after the surgery revealed a significantly higher satisfaction with physical well-being related to the chest area and psychological well-being after the SIE-BCS technique, which produced less scarring on the breast surface. Thus, the SIE-BCS technique may support a breast cancer survivor’s ability to attain a higher quality of life after the resolution of their diagnosis. Unexpectedly, we also observed that the SIE-BCS group had a lower rate of adverse effects of radiation than the C-BCS group. By removing one incision, the SIE-BCS can avoid scarring on the breast surface that may otherwise have caused discomfort from scar contracture during radiotherapy. The reduction of the side effects of radiotherapy and improvement in physical well-being related to the chest area likely contributed to the improvement in psychological well-being experienced by the patients who underwent SIE-BCS. As an aside, the full cohort of patients in our study expressed breast satisfaction and sexual well-being, with no significant differences in these two parameters between the two study groups. Although SIE-BCS has the advantage of avoiding incisions on the breast surface, this advantage may not be reflected in the Breast-Q scores because Breast-Q was not designed for the
comparison for newly developed minimal-access breast cancer operations, such as SIE-BCS. Most of the questions in the “Satisfaction with breast” section were to do with the appearance of the breasts in clothes or bras, rather than the scar length, appearance, and location. Thus, the high “Satisfaction with breast” scores in both study groups may be related to the patients’ general satisfaction with having successfully undergone BCS.

Conclusion
In this study, we introduced a novel single-port endoscopic technique for BCS called SIE-BCS that reduced the length and number of incisions on the affected breast. Logistic regression analysis showed that SIE-BCS did not increase the risk of local recurrence and metastasis. Moreover, SIE-BCS-treated patients reported significantly better scores for adverse effects of radiation, physical well-being for chest self-perception, and psychological well-being compared to C-BCS-treated patients. Because this study was retrospective with a short follow-up time, we have designed a prospective study to further demonstrate the feasibility and success of this novel breast-conserving technique. This novel technique of using insufflation and a single-port could be a safe and advantageous option for breast cancer patients who are candidates for BCS.

Abbreviations
C-BCS: Conventional breast-conserving surgery; CI: Confidence interval; OR: Odds ratio; SIE-BCS: Single-port insufflation endoscopic breast-conserving surgery.

Acknowledgements
Not applicable.

Authors’ contributions
Fang Xie: conceptualization, methodology. Zi-Han Wang: writing—original draft, writing—review and editing, funding acquisition. Shan-Shan Wu, formal analysis. Tian-Ran Gang: resources. Guo-Xuan Gao: resources. Xiang Qu: conceptualization, methodology. Zhong-Tao Zhang: project administration. All authors have read and approved the final manuscript.

Funding
This work was supported by grants from: (1) Capital’s Funds for Health Improvement and Research (2020-2-1112); and (2) Research Foundation of Beijing Friendship Hospital, Capital Medical University (yyqdkt2018-11). The funding sources had no involvement in any part of the study design, data collection, or analysis; writing; or article submission.

Availability of data and materials
The datasets generated and analyzed during the present study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
All surgical procedures and details of informed consent were approved by the ethics committee of Beijing Friendship Hospital, Capital Medical University, Beijing, China (2016-P2-070-02). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 General Surgery Department, Beijing Friendship Hospital, Capital Medical University, 95 Yong-an Road, Xi-Cheng District, Beijing 100050, China. 2 Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, 23 Mei shu guan Back Street, Dong-Cheng District, Beijing 100010, China. 3 Department of Breast Disease, Peking University People’s Hospital, 11 Xi zhi men South Street, Xi-Cheng District, Beijing 100044, China. 4 Department of Clinical Epidemiology and Evidence-Based Medicine, Beijing Friendship Hospital, 95 Yong-an Road, Xi-Cheng District, Beijing 100050, China.

Received: 31 March 2022 Accepted: 24 September 2022
Published online: 06 October 2022

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
2. DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69:438–51.
3. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.
4. Sinnadurai S, Kwong A, Hartman M, Tan EY, Bhoo-Pathy NT, Dahlui M, et al. Breast-conserving surgery versus mastectomy in young women with breast cancer in Asian settings. BJU Open. 2019;3:48–55.
5. Chen R, You S, Yin Z, Zhu Q, Jiang C, Li S, et al. Non-doctoral factors influencing the surgical choice of Chinese patients with breast cancer who were eligible for breast-conserving surgery. World J Surg Oncol. 2019;17:189.
6. Kelisall JE, McCulley SJ, Brock I, Akerlund MTE, Macmillan RD. Comparing oncoplastic breast conserving surgery with mastectomy and immediate breast reconstruction: Case-matched patient reported outcomes. J Plast Reconstr Aesthet Surg. 2017;70:1377–85.
7. Ye JC, Yan W, Christos PJ, Noni D, Ravi A. Equivalent survival with mastectomy or breast-conserving surgery plus radiation in young women aged <40 years with early-stage breast cancer: a national registry-based stage-by-stage comparison. Clin Breast Cancer. 2015;15:390–7.
8. National comprehensive cancer network. Clinical practice guidelines in oncology. Breast Cancer 2017. Published February 2017. Accessed April 6, http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
9. Pusic AL, Klassen AF, Scott AM, Klok JA, Cordeiro PG, Cano SJ. Development of a new patient-reported outcome measure for breast surgery: the BREAST-Q. Plast Reconstr Surg. 2009;124:345–53.
10. Cano SJ, Klassen AF, Scott AM, Cordeiro PG, Pusic AL. The BREAST-Q: further validation in independent clinical samples. Plast Reconstr Surg. 2012;129:293–302.
11. van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst. 2000;92:1143–50.
12. Abdul-kerim BS, Cuartero J, Hanson J, Deschênes J, Lesniak D, Sabri S. Increased risk of locoregional recurrence for women with T1-2NO triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol. 2011;29:2852–8.
13. Tenofsky PL, Dowell F, Topalovski T, Helmer SD. Surgical, oncologic, and cosmetic differences between oncoplastic and nononcoplastic breast conserving surgery in breast cancer patients. Am J Surg. 2014;207:398–402 discussion.
14. Wang Z, Han X. Clinical significance of breast-conserving surgery for early breast cancer and its impact on patient life quality of life. J buon. 2019;24:1898–904.
15. Gold M, Dunn LB, Phoenix B, Paul SM, Hamolsky D, Levine JD, et al. Co-occurrence of anxiety and depressive symptoms following breast cancer surgery and its impact on quality of life. Eur J Oncol Nurs. 2016;20:97–105.
16. Xu S, Tang P, Chen X, Yang X, Pan Q, Gui Y, et al. Novel technique for laparoscopic harvesting of latissimus dorsi flap with prosthesis implantation for breast reconstruction: a preliminary study with 2 case reports. Medicine (Baltimore). 2016;95:e5428.
17. Takahashi H, Fuji T, Nakagawa S, Inoue Y, Akashi M, Toh U, et al. Usefulness of endoscopic breast-conserving surgery for breast cancer. Surg Today. 2014;44:2037–44.
18. Ozaki S, Ohara M. Endoscopy-assisted breast-conserving surgery for breast cancer patients. Gland Surg. 2014;3:94–108.
19. Saimura M, Mitsuyama S, Anai K, Koga K, Watanabe M, Ono M, et al. Endoscopy-assisted breast-conserving surgery for early breast cancer. Asian J Endosc Surg. 2013;6:203–8.
20. Wang ZH, Ng HI, Teng CS, Ge ZC, Gao GX, Gao YG, et al. Outcomes of single-port gasless laparoscopic breast-conserving surgery for breast cancer: An observational study. Breast. J. 2019;25:461–4.
21. Lai HW, Mok CW, Chang YT, Chen DR, Kuo SJ, Chen ST. Endoscopic assisted breast conserving surgery for breast cancer: Clinical outcome, learning curve, and patient reported aesthetic results from preliminary 100 procedures. Eur J Surg Oncol. 2020;46:1446–55.
22. Ozaki S, Ohara M, Shigematsu H, Sasada T, Emi A, Masumoto N, et al. Technical feasibility and cosmetic advantage of hybrid endoscopy-assisted breast-conserving surgery for breast cancer patients. J Laparoendosc Adv Surg Tech A. 2013;23:91–9.
23. Jacobs L. Positive margins: the challenge continues for breast surgeons. Ann Surg Oncol. 2008;15:1271–2.
24. Lai HW, Chen ST, Lin YJ, Lin SL, Lin CM, Chen DR, et al. Minimal access (endoscopic and robotic) breast surgery in the surgical treatment of early breast cancer-trend and clinical outcome from a single-surgeon experience over 10 years. Front Oncol. 2021;11:739144.
25. Ammori BJ, Asmer H, Al-Najjar H, Al-Bakri H, Obaid A, Aouda F, et al. Laparoscopic versus open d2 gastrectomy for gastric cancer: a case-matched comparative study. J Laparoendosc Adv Surg Tech A. 2020;30:777–82.
26. Al-Saif FA, Aldekhayel MK, Al-Alem F, Hassanain MM, Mattar RE, Alshehabi A. Comparison study between open and laparoscopic liver resection in a Saudi tertiary center. Saudi Med J. 2019;40:452–7.
27. Chen C, Huang S, Huang A, Jia Y, Wang J, Mao M, et al. Total endoscopic thyroidecmy versus conventional open thyrodecmcy in thyroid cancer: a systematic review and meta-analysis. Ther Clin Risk Manag. 2018;14:2349–61.
28. Mosayebi A, Mojarabi B, Bonyadi Naeini A, Khodadad Hosseini SH. Modeling and comparing data mining algorithms for prediction of recurrence of breast cancer. PLoS One. 2020;15:e0237658.
29. Lertsithichai P, Sakulcharungreung B, Chirappapha P, Suvikapakornkul R, Wasuithi Y, Sukrayothin T, et al. Effect of young age, positive margins, and triple negative status on disease recurrence after breast conserving therapy. Gland Surg. 2016;5:15–23.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.